Literature DB >> 1950463

Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias.

P Mecocci1, L Parnetti, G P Reboldi, C Santucci, A Gaiti, C Ferri, I Gernini, M Romagnoli, D Cadini, U Senin.   

Abstract

Albumin and IgG were determined in serum and cerebrospinal fluid (CSF) of patients with early-onset Alzheimer's disease (AD, n. 13), senile dementia of Alzheimer type (SDAT, n. 33), vascular dementia divided into multi-infarct (MID, n. 9) and probable vascular (PVD, n. 11) dementia. Albumin and IgG ratio and IgG index were calculated. CSF albumin and albumin ratio were significantly higher in MID patients indicating an increased BBB permeability. IgG ratio and IgG index did not show any significant difference among groups. These results do not provide evidence for BBB damage in AD/SDAT, while in MID the increase of CSF albumin and albumin ratio is suggestive of BBB dysfunction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1950463     DOI: 10.1111/j.1600-0404.1991.tb04940.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

1.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

Review 2.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 3.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

4.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan.

Authors:  Seiji Shiota; Kazunari Murakami; Aoi Yoshiiwa; Kyoko Yamamoto; Shigeki Ohno; Akiko Kuroda; Kazuhiro Mizukami; Katsuhiro Hanada; Tadayoshi Okimoto; Masaaki Kodama; Kou Abe; Yoshio Yamaoka; Toshio Fujioka
Journal:  J Neurol       Date:  2011-02-19       Impact factor: 4.849

6.  Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-D-aspartate glutamate receptor antibodies in dementias.

Authors:  Mandy Busse; Ralf Kunschmann; Henrik Dobrowolny; Jessica Hoffmann; Bernhard Bogerts; Johann Steiner; Thomas Frodl; Stefan Busse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-08       Impact factor: 5.270

7.  Blood-Brain Barrier Disruption and Neurovascular Unit Dysfunction in Diabetic Mice: Protection with the Mitochondrial Carbonic Anhydrase Inhibitor Topiramate.

Authors:  Therese S Salameh; Gul N Shah; Tulin O Price; Melvin R Hayden; William A Banks
Journal:  J Pharmacol Exp Ther       Date:  2016-10-11       Impact factor: 4.030

8.  Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery.

Authors:  Udi Vazana; Ronel Veksler; Gaby S Pell; Ofer Prager; Michael Fassler; Yoash Chassidim; Yiftach Roth; Hamutal Shahar; Abraham Zangen; Ruggero Raccah; Emanuela Onesti; Marco Ceccanti; Claudio Colonnese; Antonio Santoro; Maurizio Salvati; Alessandro D'Elia; Valter Nucciarelli; Maurizio Inghilleri; Alon Friedman
Journal:  J Neurosci       Date:  2016-07-20       Impact factor: 6.167

Review 9.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

Review 10.  MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies.

Authors:  Rajikha Raja; Gary A Rosenberg; Arvind Caprihan
Journal:  Neuropharmacology       Date:  2017-10-28       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.